Century Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 10:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-04-01 to 2021-06-30 | $18.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $34.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$23.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$41.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $318.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $632.0k | us-gaap:InterestExpense |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$23.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$41.6m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | −$1.93 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | −$4.26 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$40.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $12.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $272.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $402.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $495.6m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $21.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $48.0m | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $10.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-06-30 | $447.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-011390. Last ingested by Listed: Nov 5, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.